Literature DB >> 30668617

Diagnostic Utility of UroVysion Combined With Conventional Urinary Cytology for Urothelial Carcinoma of the Upper Urinary Tract.

Naoto Sassa1, Hidehiro Iwata2,3, Masashi Kato1, Yota Murase2,3, Shuko Seko3, Toshinori Nishikimi4, Ryohei Hattori5, Momokazu Gotoh1, Toyonori Tsuzuki2.   

Abstract

OBJECTIVES: We prospectively evaluated the utility of UroVysion in urothelial carcinomas of the upper urinary tract (UCUUTs).
METHODS: Ninety patients who received nephroureterectomy for UCUUT were enrolled. We performed urinary cytology and UroVysion before nephroureterectomy. We also performed the assays on 23 volunteers without a history of urothelial carcinoma.
RESULTS: Seventy-five high-grade urothelial carcinomas (HGUCs), 10 low-grade urothelial carcinomas, and five other conditions were enrolled. Sensitivity, specificity, positive predictive value, and negative predictive value for HGUC detection by urinary cytology were 28.0%, 100.0%, 100.0%, and 31.6%, respectively; for detection by fluorescence in situ hybridization, these values were 60.0%, 84.0%, 93.8%, and 41.2%, respectively. UroVysion detected the only deletion of 9p21 in eight of 23 samples negative for HGUC by urinary cytology and in three of 23 volunteers.
CONCLUSIONS: Combining urinary cytology and UroVysion can improve the diagnostic accuracy of UCUUT. Caution is advised in diagnosing UCUUT based only on deletion of 9p21. © American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  FISH; The Paris System; Upper urinary tract; Urinary cytology; UroVysion; Urothelial carcinoma

Mesh:

Year:  2019        PMID: 30668617     DOI: 10.1093/ajcp/aqy170

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  UroVysion® predicts intravesical recurrence after radical nephroureterectomy for urothelial carcinoma of the upper urinary tract: a prospective study.

Authors:  Hidehiro Iwata; Naoto Sassa; Masashi Kato; Yota Murase; Shuko Seko; Hideji Kawanishi; Ryohei Hattori; Momokazu Gotoh; Toyonori Tsuzuki
Journal:  Int J Clin Oncol       Date:  2020-09-21       Impact factor: 3.402

Review 2.  UroVysion fluorescence in situ hybridization in urothelial carcinoma: a narrative review and future perspectives.

Authors:  Takashi Nagai; Taku Naiki; Toshiki Etani; Keitaro Iida; Yusuke Noda; Nobuhiko Shimizu; Teruki Isobe; Satoshi Nozaki; Takehiko Okamura; Ryosuke Ando; Noriyasu Kawai; Takahiro Yasui
Journal:  Transl Androl Urol       Date:  2021-04

3.  CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia.

Authors:  Daniel J Neal; Mahul B Amin; Steven C Smith
Journal:  Diagn Pathol       Date:  2020-05-26       Impact factor: 2.644

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.